ImageReady(TM) MR Conditional Pacing System Clinical Study

NCT ID: NCT01781078

Last Updated: 2019-12-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

363 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2019-09-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the SAMURAI Clinical Study is to collect data to confirm the safety, performance and effectiveness of the ImageReady System for use in the Magnetic Resonance Imaging (MRI) environment when used in accordance with the Conditions of Use included in the Boston Scientific MRI Technical Guide

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bradycardia Sinus Node Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MRI Group

Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.

Group Type EXPERIMENTAL

MRI

Intervention Type RADIATION

The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment

ImageReady System implant

Intervention Type DEVICE

Pacemaker and lead(s) implant

Control Group

Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.

Group Type EXPERIMENTAL

ImageReady System implant

Intervention Type DEVICE

Pacemaker and lead(s) implant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment

Intervention Type RADIATION

ImageReady System implant

Pacemaker and lead(s) implant

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MR Scan Single chamber pacemaker implant Dual chamber pacemaker implant Pace/ Sense pacemaker lead implant

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject must have the ImageReady System as their initial (de novo) pacing system implant
* Subject has a Class I or II indication for implantation of a single or dual chamber pacemaker according to the ACC/AHA/HRS, or ESC guidelines, as appropriate per geography
* Subject is able and willing to undergo an MRI scan without intravenous sedation
* Subject is willing and capable of providing informed consent (which can include the use of a legally authorized representative (LAR) for documentation of informed consent) and participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol
* Subject is age 18 or above, or of legal age to give informed consent specific to state and national law

Exclusion Criteria

* Subject has or has had any pacing or ICD system implants
* Subject has any MR Unsafe implants or devices with an unknown MR status, including MR Unsafe sternal wires, neurostimulators, biostimulator, metals or alloys, per labeling of each implant
* Subject has any MR Conditional implants or devices that impact the ability to conduct this protocol
* Subject needs or will need another MR scan within 14 weeks of system implant, other than that required by the SAMURAI Study
* Subject has a known or suspected sensitivity to dexamethasone acetate (DXA)
* Subject has a mechanical tricuspid heart valve
* Subject is enrolled in any other concurrent study, with the exception of local mandatory governmental registries and observational studies/registries\* that are not in conflict and do not affect the following:

* Schedule of procedures for the SAMURAI Study (i.e. should not cause additional or missed visits);
* SAMURAI Study outcome (i.e. involve medications that could affect pacing thresholds);
* Conduct of the SAMURAI Study per GCP/ ISO 14155:2011/ local regulations
* Subjects with documented permanent or persistent AF where the physician intends to implant a dual chamber pulse generator (single chamber VVIR pulse generators are acceptable)
* Subject is currently on the active heart transplant list
* Subject has documented life expectancy of less than 12 months
* Women of childbearing potential who are or might be pregnant at the time of study enrollment or ImageReady MR Conditional Pacing System implant (method of assessment upon physician's discretion)
* Subjects currently requiring dialysis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ronald Berger, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins Hospital, Carnegie 530, 600 N. Wolfe St, Baltimore, MD 21287

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner Heart Hospital

Mesa, Arizona, United States

Site Status

USC Medical Center

Los Angeles, California, United States

Site Status

University of California, San Francisco

San Francisco, California, United States

Site Status

Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Orlando Regional Medical Center

Orlando, Florida, United States

Site Status

University Community Hospital

Trinity, Florida, United States

Site Status

Emory University Hospital

Atlanta, Georgia, United States

Site Status

University of Chicago Hospital

Chicago, Illinois, United States

Site Status

Alexian Brothers Medical Center

Elk Grove Village, Illinois, United States

Site Status

Johns Hopkins Hospital

Baltimore, Maryland, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

St Mary's Duluth Clinic Regional Heart Center

Duluth, Minnesota, United States

Site Status

United Heart and Vascular Clinic

Saint Paul, Minnesota, United States

Site Status

Billings Clinic

Billings, Montana, United States

Site Status

Hackensack University Medical Center

Hackensack, New Jersey, United States

Site Status

Long Island Jewish Medical Center

New Hyde Park, New York, United States

Site Status

OhioHealth Research and Innovation Institute

Columbus, Ohio, United States

Site Status

Trinity West Hospital

Steubenville, Ohio, United States

Site Status

Abington Memorial Hospital

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Avera Heart Hospital of South Dakota

Sioux Falls, South Dakota, United States

Site Status

Texas Cardiac Arrhythmia Research Foundation

Austin, Texas, United States

Site Status

Medical City Dallas Hospital

Dallas, Texas, United States

Site Status

Trinity Mother Health Systems

Tyler, Texas, United States

Site Status

Martha Jefferson Hospital

Charlottesville, Virginia, United States

Site Status

Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Site Status

Virginia Commonwealth University Health System

Richmond, Virginia, United States

Site Status

University of Washington Medical Center

Seattle, Washington, United States

Site Status

Froedtert Memorial Lutheran Hospital - Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

St Vincent's Hospital

Melbourne, Victoria, Australia

Site Status

Institut Universitaire de Cardiologie et de Pneumologie de Quebec

Ste Foy, Quebec, Canada

Site Status

Queen Mary Hospital

Hong Kong, Hong Kong, China

Site Status

Hillel Yaffe Medical Center

Hadera, , Israel

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

The Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Sheba Medical Center

Tel Litwinsky, , Israel

Site Status

Institut Jantung Negara

Kuala Lumpur, , Malaysia

Site Status

University Malaya Medical Center

Kuala Lumpur, , Malaysia

Site Status

National Heart Centre

Singapore, , Singapore

Site Status

National University Hospital, Singapore

Singapore, , Singapore

Site Status

Tan Tock Seng Hospital

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada China Israel Malaysia Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BSC-CDM00047737

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

China 3T MRI Study
NCT06038123 COMPLETED NA
Myocardial Perfusion Imaging Galmydar Rest/Stress
NCT05625490 COMPLETED EARLY_PHASE1
Accent Cardiac MRI Study
NCT02041702 COMPLETED NA